MET and gastric cancer: The efficacy of the combined treatment (EM127 and SU11274) in inhibiting the phosphoactivation of MET, ERK 1/2, and AKT was validated by immunoblotting analysis in both AGS and NCI-N87 GC cell lines (Supplementary Figure S1b).